Announced
Completed
Financials
Tags
biopharmaceutical company
drug development
Single Bidder
Friendly
Pharmaceuticals
Majority
Public
Cross Border
Acquisition
Canada
oncology
Completed
Synopsis
GlaxoSmithKline, a science-led global healthcare company, completed the acquisition of Sierra Oncology, a late-stage clinical drug development biopharmaceutical company, for $1.9bn. "Sierra Oncology complements our commercial and medical expertise in haematology. Momelotinib offers a differentiated treatment option that could address the significant unmet medical needs of myelofibrosis patients with anaemia, the major reason patients discontinue treatment. With this proposed acquisition, we have the opportunity to potentially bring meaningful new benefits to patients and further strengthen our portfolio of specialty medicines," Luke Miels, GSK CCO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.